Acoltremon

Class
Thermoreceptor agonists
Subclass
TRPM8 activators
Substance name
Acoltremon
Brand names
Tryptyr®
Common formulations
Ophthalmic solution
Dosage and administration
Adults patients
Treatment of dry eye disease
•
1 gtt OPHTH BID (0.003% ophthalmic solution)
Indications for use
Labeled indications
Adults
•
Treatment of dry eye disease
Safety risks
Warnings and precautions
Contact lens damage
•
Use caution in patients wearing contact lenses. Advise patients not to administer the drops while wearing contact lenses. Contact lenses should be removed before administration and may be reinserted 15 minutes afterward.
Eye injury
•
Maintain a high level of suspicion, as eye injury and contamination may occur with improper handling. Advise patients not to touch the vial tip to the eye or any other surface to avoid the risk of eye injury and contamination.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
No guidance available.
Renal replacement therapy
Any modality
•
No guidance available.
Hepatic impairment
Any severity
•
No guidance available.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Insufficient evidence. Systemic exposure to acoltremon from ocular administration is negligible.
Breastfeeding
Use only if benefits outweigh potential risks.
•
Systemic exposure to acoltremon from ocular administration is negligible.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Burning sensation in the eyes, stinging sensation in the eyes, eye pain
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource